From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2022 call → NOWe need to determine if management describes a recent transition to being an approved/specified/listed/etc. choice inside buyers' systems, such that future business can arrive without discrete selling events, and that this is new enough that most volume is ahead. Scan the transcript for relevant statements. Amy Taylor discusses distribution gains: "In Q1, almost 250,000 incremental households purchased Zevia in a Club store." That's about new households, not about being placed into a system. She mentions "13,000 new points of distribution driven largely by moving from five flavors to a brand blocked 12 flavors, and moving from six packs to a cardboard wrapped eight pack in the CSP aisle of one of the two major players nationwide." That's about distribution expansion, not about being on a preferred list or formulary. Also "this retailer has also expanded from two to four of our kids flavors and the other top mass retailer has also newly taken on four of our kids flavors, penetrating a new portion of 1,500 stores." That's about getting shelf space, not about being a default in a procurement system. The question asks about being an approved, specified, listed, qualified, registered, reimbursed, or pre-authorized choice inside buyers' own purchasing systems. The transcript talks about distribution, shelf placement, new points of distribution, but not about being added to a formulary, preferred supplier list, or similar. It's about retail distribution, which is still a selling event per order? Actually, once a product is on a shelf, consumers choose it, but that's not a "discrete selling event" in the sense of a B2B contract. However, the question is about the company being placed into a system where purchases flow without re-arguing. Retail shelf placement is a form of being listed, but it's not a new phenomenon; it's the standard way of going to market. The company has been selling in retail for years. The transcript mentions new distribution, but that's not a recent transition to a new status; it's ongoing expansion. Also, the question asks if management conveys that this access status is new enough that most volume is still ahead. The transcript does not explicitly say that. It talks about growth and distribution gains, but not about a specific gateway that will unlock future volume. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.